A 64-year-old Australian man was diagnosed with stage 3 breast cancer after his wife noticed bloodstains on his shirt, a case doctors say highlights that men can and do get the disease. Meanwhile, advances in precision medicine now allow breast cancer treatment to be tailored to each tumour’s biology and the patient’s overall health.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
New clinical trial data show trastuzumab deruxtecan plus pertuzumab extends progression-free survival as first-line therapy, while MRI-guided treatment shortening reduces toxicity in neoadjuvant settings for HER2-positive breast cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07701941 |
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT00310180 |
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) |
ACTIVE_NOT_RECRUITING | PHASE3 |
